PSMA‐targeted imaging and therapy are current clinical practices in prostate cancer management utilizing radionuclide‐conjugated small PSMA‐binding tracers.[25] This highlights PSMA's potential as a target for novel therapeutic strategies aimed at addressing advanced stages of PCa. The gene discussed is FOLH1; the disease is posterior cortical atrophy.